(Q34718219)

English

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

Europe PubMed Central

Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Michael O'Dwyer

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

La Rosée P

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

O'Dwyer ME

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Druker BJ

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1213-1219

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

AraC-based pharmacotherapy of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Differentiation therapy of human cancer: basic science and clinical applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel therapies for chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

New agents for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of DNA methylation in mammalian epigenetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Homoharringtonine: history, current research, and future direction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of modelling in joint action studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402555

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402555

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12094245%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34718219&oldid=2196976377"